Information

The Centre's foundation was instigated and led by the Surgical Clinic A main focus: abdominal surgery for cancer and the Medical Clinic C main focus: gastroenterology and gastrointestinal cancers.

The centre aims to provide patients with the latest treatment options available and to ensure that treatment is coordinated in an effective manner. Our treatment meets the high quality standards established by the German Cancer Society's current "S3 guidelines" for colorectal cancer. Our high standards of care are made possible by our extensive network of partners. We collaborate closely with a number of the Hospital's clinics and institutes as well as having close ties with medical practices and social organisations from the wider Ludwigshafen area. In addition to offering treatment for the physical manifestations of disease, our centre strives to provide patients with appropriate rehabilitation measures, psycho-oncological support and social support services, as well as ensuring a seamless transition between a patient's inpatient and outpatient treatment.

At the Bowel Centre, appropriate care is never in short supply: Specialists from inpatient and outpatient services work together to provide a holistic treatment approach.

For further information on the Bowel Centre, please refer to the Centre's website: www.darmzentrum-rheinpfalz.de

Our Partners

The Bowel Centre represents a network of specialists from within the tertiary care hospital environment, outpatient services, as well as associated partners. These various experts work closely together to deliver the most up-to-date methods of screening and treatment for colorectal cancers.

A summary diagram of how the network is organised and who the partners are, is available for download below.

The main purpose of the Bowel Centre's network of experts is to ensure seamless operation and close cooperation between the partners, all of whom have equal input.

Research

Medical advances can only be implemented in practice once research studies have provided the necessary evidence.
This is particularly true for chemotherapy drugs, which have to undergo rigorous scientific testing before they can be made available to patients.

The Bowel Centre supports the development of new drugs and is keen to be able to provide its patients with the very latest that pharmaceutical research and development has to offer.

This is why we are currently involved in a number of studies:

  • DACHS Study Darmkrebs: Chancen der Verhütung durch Screening [Colorectal cancer: chances for prevention through screening]
  • Transrectal vacuum assisted drainage – A new method of treating anastomotic leakage after rectal resection
  • Optimierung der medizinischen Diagnostik und Therapieplanung bei kolorektalen Tumoren mit Hilfe der F-18-Deoxyglukose (FDG), Positronenemissionstomographie (PET) und Genexpressionsbestimmungen (GenPET Colon-2008) [Optimization of the medical diagnostics and therapy managing in colorectal tumors using F-18-Deoxyglucose (FDG) positron emission tomography (PET) and gene expression data (GenPET Colon-2008)]
  • Einfluss einer perioperativen Volumenersatztherapie mit HES 130/0,4 (Volulyte®) auf die Rate postoperativer Komplikationen [The effect of perioperative volume replacement therapy with HES 130/0,4 (Volulyte®) on postoperative complications]
  • Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with fluoropyrimidine and bevacizumab vs bevacizumab alone vs. no maintanance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer
  • Characterization of new tumour markers for the early detection of colorectal carcinoma
  • FIRE III
  • LUVIK

For any study-related questions please contact Frau Ulrike Doppler, Medical Clinic C on 0621 503 2122.